Kiniksa Pharmaceuticals International, plc — Net Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/668df63d-7a00-493c-a449-d64ecc5f91a2/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $59.0M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-019168 |
| FY 2024 | $-43.2M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-001505 |
| FY 2023 | $14.1M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-002005 |
| FY 2022 | $183.4M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-002684 |
| FY 2021 | $-157.9M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-001932 |
| FY 2020 | $-161.4M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-001821 |
| FY 2019 | $-161.9M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-002081 |
| FY 2018 | $-103.2M | 2018-01-01 – 2018-12-31 | evidence 0001558370-19-001857 |
| FY 2017 | $-64.9M | 2017-01-01 – 2017-12-31 | evidence 0001558370-19-001857 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Kiniksa Pharmaceuticals International, plc — all facts · Revenue · Operating Income